// App-Quantinova.ai

: Tocilizumab to Prevent Infusion-Related Events in Patients with Chronic Lymphocytic Leukemia and Co-Morbidities Treated with Obinutuzumab and Chlorambucil: Results from the Randomized Phase Ib GALACTA Trial

Researchers

Presenter

  • Ciara Louise Freeman

Principal Investigators

  • Sebastian Bttcher

  • Javier De la Serna

  • Julio Delgado

  • Franca Falzetti

  • Marco Gobbi

  • Sandra Lejniece

  • Maria Chiara Di Bernardo

  • Navita L Mallalieu

  • Tina Nielsen

  • Andrea Knapp

  • John G. Gribben

Medical Centers

  • BC Cancer Centre for Lymphoid Cancer,Vancouver,Canadá

  • University Hospital Rostock, Department of Internal Medicine B, Rostock, Germany

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Ospedale Santa Maria della Misericordia, Perugia, Italy

  • Riga East Clinical University Hospital, Riga, Latvia

  • On assignment to F. Hoffmann-La Roche Ltd, Basel, Switzerland

  • Roche Innovation Center, New York, NY

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Locations

  • Canada

  • Germany

  • Spain

  • Italy

  • Latvia

  • Switzerland

  • United States

  • United Kingdom

Companies

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • B-lymphocyte antigen CD20

  • Cardiac phospholamban

  • Creatinine

  • Lymphocyte count

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • chlorambucil

  • Tocilizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • I

Study Id's

  • NCT02336048

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved